MEA Pacemaker Market

MEA Pacemaker Market Size (2023 to 2028)

The size of the Middle East and Africa Pacemaker Market is predicted to grow at a CAGR of 2.45% from 2023 to 2028. As a result, the market value is expected to grow from USD 0.26 billion in 2023 to USD 0.29 billion by 2028.

A pacemaker is a medical device that sends tiny electrical impulses to the cardiac muscles to maintain a healthy heart rate or stimulate the heart's lower chambers. Syncope, congestive heart failure, and hypertrophic cardiomyopathy are among the conditions treated with this drug. The pacemaker is put by a minimally invasive surgical procedure called epicardial or endocardial. The leads and pacemaker are implanted through an incision made in the patient's chest during this surgery.

The introduction of technologically advanced pacemakers such as leadless pacemakers and MRI-safe pacemakers and rising incidences of cardiovascular diseases (CVDs), increasing costs of cardiac disease management, is favorable. Therefore, the MEA market for pacemakers is primarily driven by government policies and the development of technologically sophisticated pacemakers such as leadless pacemakers and MRI-safe pacemakers.

Increased desire for minimally invasive procedures, increased financing from corporate and government organizations for the healthcare sector, and an increase in the frequency of cardiovascular disorders are all driving the expansion of the Middle East and Africa pacemaker market.

Technological developments resulting in product development, such as developing a demand external pacemaker that activates only when it detects abnormal cardiac rhythms, avoiding competing with the heart's natural pacemaker, are pushing a faster market acceptance of external pacemakers.

The new coronavirus seriously harmed patients with cardiovascular problems. The pandemic's expansion had had a massive economic impact on the healthcare and medical equipment industries. Recent pacemaker product recalls, and the exorbitant cost of these devices may slightly jeopardize the market growth during the forecast period. The growing senior population in this region and the increased prevalence of cardiovascular illnesses such as atrial fibrillation, arrhythmias, and heart failure. Increased risk factors such as obesity, hypertension, smoking, and diabetes, among others, have impacted cardiovascular health in the UAE due to rapid socio-economic development.

Check cardiac pacing devices for moisture intrusion, which could cause an electrical short-circuit and shorten battery life. This recall was classified as a Class I recall, which is the most dangerous sort of recall in which the use of the item could result in serious injuries or even death. If the number of product recalls increases in the near future, that is expected to hamper the adoption rate of pacemakers.

This research report on the Middle East and Africa pacemaker market has been segmented and sub-segmented into the following categories:

 By Product:

• Implantable
• External Pacemakers

By Application:

• Unipolar
• Bipolar Pacemakers

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the MEA regional market accounted for a minor share in the global market in 2020; however, the market is expected to grow at a promising rate during the forecast period. The leading players market penetration and vast unexplored prospects are expected to help the market in the near future. In addition, investments in the healthcare industry, particularly in the United Arab Emirates and Kuwait, are further expected to accelerate the market’s growth rate. Furthermore, countries are increasingly concentrating on developing effective cardiac diagnosis and treatment centers. As a result of these factors, the region's market is predicted to increase during the forecast period.

KEY MARKET PLAYERS:

Companies playing a vital role in the MEA pacemaker market profiled in this report are Medtronic, Sorin Group, Biotronik GmbH & Co. KG., Boston Scientific Corporation, Vitatron, St. Jude Medical, Inc., and Zoll Medical Corporation.